Description
Your doctor may prescribe Zejula for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Zejula is a poly (ADP-ribose) polymerase (PARP) inhibitor. These drugs work by interfering with the DNA repair mechanisms in cancer cells, ultimately leading to cell death and slowing the progression of the disease.
Fact Table
|
Formula
|
C19H20N4O5
|
License
|
US FDA, EMA
|
Bioavailability
|
73%
|
Legal status
|
Prescription only (?)
|
Chemical Name
|
2-[4-[(3S)-3-piperidinyl]phenyl]-2H-indazole-7-carboxamide
|
Elimination half-life
|
36 hours
|
Dosage (Strength)
|
100 mg capsules
|
Pregnancy
|
Contraindicated
|
Brands
|
Zejula
|
Protein binding
|
83%
|
PubChem CID
|
24958200
|
MedlinePlus
|
a617038
|
ChEBI
|
CHEBI:134722
|
ATC code
|
L01XX54
|
DrugBank
|
DB12362
|
KEGG
|
D10867
|
Routes of administration
|
Oral
|
Directions
The usual dosage is 200-300 mg by mouth once daily. Zejula may be taken with or without food.
Ingredients
The active ingredient in Zejula is niraparib.
Interactions
There are no significant drug-drug interactions with Zejula
Cautions
Cardiovascular side effects like changes in blood pressure and heart rate can occur. Patients should have their blood pressure and heart rate monitored at least weekly for the first two months, then monthly for the first year, and periodically thereafter. Management may include the use of antihypertensive medications and adjustments to the Zejula dose if necessary.
Zejula has been associated with cases of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), some of which have been fatal. It is crucial to monitor patients for hematological toxicity and discontinue the medication if MDS/AML is confirmed.
Bone marrow suppression is a significant risk. It is recommended to test blood counts weekly for the first month, then monthly for eleven months, and then periodically thereafter to monitor for clinically significant changes.
Zejula can cause harm to a fetus. Females of reproductive potential should be advised of the potential risks to a fetus and the necessity of using effective contraception while on this medication.
Side Effects
Common adverse effects of Zejula may include:
- Acute myeloid leukemia
- Anemia
- Anemia, Grade 3 or 4
- Constipation
- Decrease in appetite
- Dyspnea
- Gastrointestinal perforation
- Headache
- Hypertension
- Hypertensive crisis
- Insomnia
- Leukopenia, Grade 3 or 4
- Myelodysplastic syndrome
- Nasopharyngitis
- Nausea
- Neutropenia
- Neutropenia, Grade 3 or 4
- Pancytopenia
- Perforation of small intestine
- Pleural effusion
- Posterior reversible encephalopathy syndrome
- Rash
- Thrombocytopenia
- Thrombocytopenia, Grade 3 or 4
- Vomiting
References
Zejula [package insert]. Research Park Triangle, NC: GlaxoSmithKline; April 2020.
About Dr. Conor Sheehy (Page Author)
Dr. Sheehy (BSc Molecular Biology, PharmD) works a clinical pharmacist specializing in cardiology, oncology, and ambulatory care. He’s a board-certified pharmacotherapy specialist (BCPS), and his experience working one-on-one with patients to fine tune their medication and therapy plans for optimal results makes him a valuable subject matter expert for our pharmacy. Read More....
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 14607